Eli Lilly announced its acquisition of Verve Therapeutics for up to $1.3 billion, integrating Verve's gene-editing technology targeting cardiovascular disease into its pipeline. Verve's lead asset, VERVE-102, demonstrated promising Phase Ib results in lowering LDL cholesterol through in vivo editing of PCSK9. This deal underscores Lilly’s strategic expansion into one-time gene therapies aimed at transforming chronic care paradigms within cardiometabolic diseases.